By definition, CAR-T cell therapy modifies a patient's T cells in order to target cancer cells, using a special receptor called a chimeric antigen receptor (CAR). These engineered T cells are then multiplied and infused back into the patient to attack cancer cells. It's primarily used for some blood cancers and is under research for other cancer types (National Cancer Institute). Below, we feature Novartis' CAR-T cell therapy key research areas, which aim to advance the development of this treatment further.
Novartis Key CAR-T Research Areas
FIG. 1. Novartis Key CAR-T Research Areas. Key areas for research in both hematologic and solid tumor CAR-T cell therapy.
Identify new tumor targets
Blood cancers: BCMA, CD22, and CD123
Solid tumors: EGFRv3, et al.
Reduce the immunosuppressive effect on the tumor microenvironment
Addition of checkpoint inhibitor
Enhance persistence and response
Enhance CAR-T persistence and response through
Dual receptor chimeric antigen receptors (CARs)
New costimulatory domains
B-cell receptor (BCR) signaling inhibitors
Reduce toxic on-target and off-target effects
Reduce off-target effects [e.g., cytokine release syndrome (CRS)]
Investigate new technologies
New technologies may improve the therapy
Natural killer (NK) cell receptors
Gamma/delta T cells
in vivo CAR-T cells
Explore allogeneic off-the-shelf technology
Simplifies manufacturing process
Explore gene-editing tools
CRISPR/Cas9 and RNAi
Are you a CRO, CMO, or Biopharma vendor? Our list of 100's of biopharma companies with cell therapy products would be perfect for your sales and business development activities. Access our free report here: https://www.biopharmiq.com/cell-therapy-companies-report
2/1/2024 - EJV
This article is not investment or legal advice.